EV68-228-N is under clinical development by KBio and currently in Phase I for Enterovirus Infections. According to GlobalData, Phase I drugs for Enterovirus Infections have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EV68-228-N’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EV68-228-N overview
EV68-228-N is under development for the treatment of EV-D68 infection and acute flaccid myelitis (AMF). It is a monoclonal antibody acts against enterovirus EV-D68 capsid protein and is administered through intravenous route. It is being developed based on RP3 platform.
KBio overview
KBio, Inc. is a Pharmaceuticals and Healthcare company that provides drug development services. The company is Headquartered in Owensboro, Kentucky, The U.S.
For a complete picture of EV68-228-N’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.